Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 6,030 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 264,993 shares of the biopharmaceutical company's stock after selling 6,030 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS's holdings in Gilead Sciences were worth $24,477,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Avior Wealth Management LLC grew its stake in shares of Gilead Sciences by 1.2% in the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company's stock valued at $782,000 after buying an additional 108 shares during the period. Southland Equity Partners LLC grew its stake in Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock valued at $289,000 after acquiring an additional 110 shares during the period. Berkshire Bank increased its holdings in shares of Gilead Sciences by 3.4% during the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock valued at $314,000 after acquiring an additional 111 shares in the last quarter. CFO4Life Group LLC raised its position in shares of Gilead Sciences by 2.7% during the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock worth $394,000 after purchasing an additional 112 shares during the period. Finally, GHP Investment Advisors Inc. lifted its holdings in shares of Gilead Sciences by 1.1% in the 4th quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company's stock worth $1,049,000 after purchasing an additional 122 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Morgan Stanley boosted their price target on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a research note on Tuesday, March 11th. Bank of America increased their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price target for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $104.52.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 302,785 shares of company stock worth $30,503,250 in the last quarter. 0.16% of the stock is owned by company insiders.

Gilead Sciences Stock Performance

Shares of GILD traded up $1.15 during trading hours on Tuesday, hitting $107.89. The company's stock had a trading volume of 8,444,141 shares, compared to its average volume of 6,795,009. The company has a market cap of $134.36 billion, a price-to-earnings ratio of 291.59, a PEG ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The business has a 50 day simple moving average of $104.01 and a two-hundred day simple moving average of $94.15. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.93%. Gilead Sciences's dividend payout ratio is 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.